DLEC/CLEC4C/BDCA-2 Antibody (124B3.13)

Product Discontinued

DLEC/CLEC4C/BDCA-2 Antibody (124B3.13) Summary

• Immunogen: Human recombinant CLEC4C.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CLEC4C
• Purity: Ion exchange chromatography

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin 10ug/ml

Reactivity Notes

Human and Rat.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: Tris-NaCl (pH 8.0)
• Preservative: No Preservative
• Concentration: 0.5 mg/ml
• Purity: Ion exchange chromatography

Notes

This product is manufactured by Eurobio Scientific (formerly Dendritics) and distributed by Novus Biologicals.

Alternate Names for DLEC/CLEC4C/BDCA-2 Antibody (124B3.13)

• BDCA2
• BDCA-2
• BDCA2MGC125791
• blood dendritic cell antigen 2 protein
• Blood dendritic cell antigen 2
• CD303 antigen
• CD303
• CLEC4C
• CLECSF11
• CLECSF11PRO34150
• CLECSF7
• C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 11
• C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamilymember 7
• C-type lectin domain family 4 member C
• C-type lectin superfamily member 7
• dendritic cell lectin b
• Dendritic lectin
• DLEC
• DLECMGC125792
• HECL
• HECLMGC125793
• MGC125789
• PRO34150

Background

CLEC4C is a type II membrane glycoprotein of 213 amino acids with a molecular mass of 25 kD which belongs to the group II of human calcium-dependent (C-type) lectin receptors (CLRs) with a single carbohydrate recognition domain (CRD) predicting mannose-type specificity. Protein expression is restricted to the immature plasmacytoid dendritic cell subset on which BDCA2 is involved in ligand internalization, processing and presentation, as well as in inhibition of IFN- a/b synthesis.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for DLEC/CLEC4C/BDCA-2 Antibody (DDX0043P-100)(18)

Publications using DDX0043P-100

• Pang L, Ng KT, Liu J et al. Plasmacytoid dendritic cells recruited by HIF-1 alpha /eADO/ADORA1 signaling induce immunosuppression in hepatocellular carcinoma Cancer letters 2021-09-16 [PMID: 34536555] (IHC-P, Human)
• Urakawa S, Yamasaki M, Makino T et al. The impact of ICOS+ regulatory T cells and Helicobacter pylori infection on the prognosis of patients with gastric and colorectal cancer: potential prognostic benefit of pre-operative eradication therapy Cancer Immunol. Immunother. 2020-08-16 [PMID: 32803278]
• Saito Y et al. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma. Cancer Immunol Res 2015-12-01 [PMID: 26297710]
• Strieder LR et al. Oral syphilis: report of three cases and characterization of the inflammatory cells. Ann Diagn Pathol 2015-01-01 [PMID: 25736987]
• Abou Rahal J et al. Plasmacytoid dendritic cells in alopecia areata: missing link. J Eur Acad Dermatol Venereol 2016-01-01 [PMID: 25545019]
• Valenzuela RA, Suter SR, Ball-Jones AA et al. Base modification strategies to modulate immune stimulation by an siRNA. Chembiochem. 2015-01-19 [PMID: 25487859] (IHC-P, Human)
• Poposki JA et al. Elevated presence of myeloid dendritic cells in nasal polyps of patients with chronic rhinosinusitis. Clin Exp Allergy 2015-02-01 [PMID: 25469646]
• Mimiola E et al. Rapid reconstitution of functionally active 6-sulfoLacNAc(+) dendritic cells (slanDCs) of donor origin following allogeneic haematopoietic stem cell transplant. Clin Exp Immunol 2014-10-01 [PMID: 24853271]
• Julia F et al. Blastic plasmacytoid dendritic cell neoplasms: clinico-immunohistochemical correlations in a series of 91 patients. Am J Surg Pathol 2014-05-01 [PMID: 24441662]
• Bonaccorsi I et al. Membrane transfer from tumor cells overcomes deficient phagocytic ability of plasmacytoid dendritic cells for the acquisition and presentation of tumor antigens. J Immunol 2014-01-15 [PMID: 24337377]
• Boiocchi L et al. BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells. Blood 2013-07-11 [PMID: 23847189]
• Prete F et al. Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med 2013-02-01 [PMID: 23337808]
• Pagano L et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica 2013-02-01 [PMID: 23065521]
• Stary G et al. Glucocorticosteroids modify Langerhans cells to produce TGF-beta and expand regulatory T cells. J Immunol 2011-01-01 [PMID: 21135170]
• Vermi W et al. Spontaneous regression of highly immunogenic Molluscum contagiosum virus (MCV)-induced skin lesions is associated with plasmacytoid dendritic cells and IFN-DC infiltration. J Invest Dermatol 2011-02-01 [PMID: 20739948]
• Tassone L et al. Defect of plasmacytoid dendritic cells in warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome patients. Blood 2010-12-02 [PMID: 20736454]
• Jegalian AG et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010-11-01 [PMID: 20663945]
• Vermi W et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology 2009-01-01 [PMID: 19625100]

Bioinformatics

• Gene Symbol: CLEC4C
• Uniprot:
  • Q8WTT0()